<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111913</url>
  </required_header>
  <id_info>
    <org_study_id>ALTER-L028</org_study_id>
    <nct_id>NCT04111913</nct_id>
  </id_info>
  <brief_title>A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer</brief_title>
  <official_title>An Open, Single-arm, Multi-center Exploratory Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug&#xD;
      Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing&#xD;
      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with&#xD;
      multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance&#xD;
      to new angiogenesis. The trial is to evaluate the efficacy and safety of sequential anlotinib&#xD;
      followed by EP regimen plus concurrent radiotherapy for unresectable stage III non-small cell&#xD;
      lung cancer(NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival (PFS)</measure>
    <time_frame>Approximately 12 months.</time_frame>
    <description>Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The recurrence rate in 12-month</measure>
    <time_frame>12 months.</time_frame>
    <description>The proportion of patients with disease progression within 12 months of the initiation of consolidation treatment with anlotinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The recurrence rate in 24-month</measure>
    <time_frame>12 months.</time_frame>
    <description>The proportion of patients with disease progression within 24 months of the initiation of consolidation treatment with anlotinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The disease control rate in 6-month</measure>
    <time_frame>6 months.</time_frame>
    <description>The proportion of CR, PR, and SD within 6 months of the initiation of consolidation treatment with anlotinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The disease control rate in 12-month</measure>
    <time_frame>12 months.</time_frame>
    <description>The proportion of CR, PR, and SD within 12 months of the initiation of consolidation treatment with anlotinib.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Unresectable Stage III Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>anlotinib and chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anlotinib: 12 mg, po, qd, on day1-14 of a 21 days cycle; anlotinib will be administrated to 2 cycles for induction before the 2 cycles of chemoradiation and anlotinib will be administrated up to 1year or disease progression for maintenance treatment.&#xD;
EP regimen: cisplatin 50mg/m2, d1, 8, 29, 36; etoposide 50mg/m2, d1~5, d29~33. Radiotherapy program: 2 Gy / time / d, 5 d / week;PTV radiotherapy 60~66Gy/30~33 times/6~7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>anlotinib once daily on days 1-14 of 21days cycle.</description>
    <arm_group_label>anlotinib and chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent. Willingness and ability to comply with scheduled&#xD;
             visits, treatment plans, laboratory tests, and other study procedure.&#xD;
&#xD;
          2. ≥ 18 and ≤ 70 years of age within male and female.&#xD;
&#xD;
          3. Histologically confirmed，locally advanced NSCLC of stage IIIA/IIIB.&#xD;
&#xD;
          4. Unresectable stage IIIA and stage IIIB with pathological evidence of the following&#xD;
             images or lymph nodes:&#xD;
&#xD;
               1. Multiple metastases of the mediastinal lymph nodes are transferred into a massive&#xD;
                  mass or multiple sites (IIIA: T1-3N2 or IIIB: T4N2)&#xD;
&#xD;
               2. Contralateral hilar, mediastinal lymph nodes, or the same, contralateral scalene&#xD;
                  or supraclavicular lymph node metastasis (IIIB: T1-4N3)&#xD;
&#xD;
               3. The lesion invades the heart, aorta and esophagus (IIIB: T4N0-1)&#xD;
&#xD;
          5. Life expectancy of more than 3 months.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group(ECOG)performance scale 0-1.&#xD;
&#xD;
          7. Weight loss ≤5% in the last 3 months since enrollment.&#xD;
&#xD;
          8. Good lung function (predicted FEV1 ≥1 liter), no history of bronchial pneumonia,&#xD;
             tracheobronchial disease and upper respiratory tract bleeding.&#xD;
&#xD;
          9. None previous chemotherapy or targeted therapy.&#xD;
&#xD;
         10. Adequate hepatic, renal, heart, and hematologic functions (Absolute Neutrophil&#xD;
             Count(ANC) ≥ 1.5×109/L, Platelet (PLT) ≥ 100×109/L, Hemoglobin(HB) ≥ 90 g/L, total&#xD;
             bilirubin within 1.5×the upper limit of normal(ULN), and serum transaminase≤2.5×the&#xD;
             Upper Limit Of Normal(ULN), serum creatine ≤ 1.25 x Upper Limit Of Normal(ULN),&#xD;
             creatinine clearance rate ≥ 45ml/min.&#xD;
&#xD;
         11. For women of child-bearing age, the pregnancy test results (serum or urine) within 7&#xD;
             days before enrolment must be negative. They will take appropriate methods for&#xD;
             contraception during the study until the 8th week post the last administration of&#xD;
             study drug. For men (previous surgical sterilization accepted), will take appropriate&#xD;
             methods for contraception during the study until the 8th week post the last&#xD;
             administration of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. small cell lung cancer (including small cell and non-small cell mixed lung cancer).&#xD;
&#xD;
          2. Radiologically documented evidence of tumor lesions from large vessels ≤ 5mm or major&#xD;
             blood vessel invasion or encasement by cancer; Obvious cavity or necrosis formed in&#xD;
             the tumor.&#xD;
&#xD;
          3. History and complication:&#xD;
&#xD;
               1. Less than 4 weeks from the last clinical trial or participating in other clinical&#xD;
                  studies.&#xD;
&#xD;
               2. Other active malignancies that require simultaneous treatment.&#xD;
&#xD;
               3. History of malignancy except cured basal cell skin cancer, or carcinoma in situ&#xD;
                  of the cervix, or superficial bladder cancer.&#xD;
&#xD;
               4. Patients with previous anti-tumor treatment-related adverse reactions (excluding&#xD;
                  hair loss) did not return to NCI-CTCAE ≤ 1 level.&#xD;
&#xD;
               5. Coagulation disfunction（INR&gt;1.5 or PT&gt;Upper Limit Of Normal(ULN)+4s or Activated&#xD;
                  Partial Thromboplastin Time (APTT) &gt;1.5 Upper Limit Of Normal(ULN)）, hemorrhagic&#xD;
                  tendency or receiving the therapy of thrombolysis or anticoagulation.&#xD;
&#xD;
               6. Renal insufficiency. Urine protein≥++, and 24h urine protein quantitation≥1.0g.&#xD;
&#xD;
               7. Patients had major surgery or severe trauma before enrollment. The effects of&#xD;
                  surgery or trauma have been eliminated for less than 14 days.&#xD;
&#xD;
               8. Severe acute or chronic infection requiring systemic treatment.&#xD;
&#xD;
               9. Patients who suffered from grade II or above myocardial ischemia or myocardial&#xD;
                  infarction, uncontrolled arrhythmias (including QT interval male ≥ 450 ms, female&#xD;
                  ≥ 470 ms). Grade III-IV cardiac insufficiency according to New York Heart&#xD;
                  Association(NYHA) criteria or echocardiography check: left ventricular ejection&#xD;
                  fraction (LVEF)&lt;50%.&#xD;
&#xD;
              10. Peripheral neuropathy with ≥CTCAE 2 degrees currently present, except for trauma.&#xD;
&#xD;
              11. Respiratory syndrome (≥CTC AE grade 2 dyspnea).&#xD;
&#xD;
              12. Symptomatic serous effusion requiring treatment .(including hydrothorax, ascites,&#xD;
                  hydropericardium)&#xD;
&#xD;
              13. Long-term untreated wounds or fractures（in addition to tumor-induced pathological&#xD;
                  fractures).&#xD;
&#xD;
              14. Decompensated diabetes or other remedies for high-dose glucocorticoid therapy.&#xD;
&#xD;
              15. Significant factors that influence the ingestion and absorption of medicine,&#xD;
                  (e.g. unable swallow, chronic diarrhea and intestinal obstruction.&#xD;
&#xD;
              16. Clinically significant hemoptysis occurred within 3 months prior to enrollment&#xD;
                  (daily hemoptysis greater than 50 ml). History of clinically relevant major&#xD;
                  bleeding event=&lt;3 months (e.g. gastrointestinal hemorrhage, Hemorrhagic acne，&#xD;
                  bleeding gastric ulcer, occult blood test ≥ (++), and vasculitis.&#xD;
&#xD;
              17. Planned systemic anti-tumor therapy, including cytotoxic therapy, signal&#xD;
                  transduction inhibitors, immunotherapy, within 4 weeks prior to enrollment in&#xD;
                  other anti-cancer drug clinical trials or within 4 weeks prior to grouping or&#xD;
                  during the study.&#xD;
&#xD;
          4. Physical examination and laboratory inspection:&#xD;
&#xD;
               1. Have a positive history of human immunodeficiency virus (HIV) test or have&#xD;
                  acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
               2. Untreated active hepatitis (Hepatitis B: HBsAg-positive and HBV DNA ≥ 500IU/mL;&#xD;
                  Hepatitis C: HCV RNA-positive and abnormal liver function); Combined hepatitis B&#xD;
                  and C infection&#xD;
&#xD;
          5. At the discretion of the investigator, the patient may have other factors that may&#xD;
             cause the study to be terminated midway, such as other serious illnesses or serious&#xD;
             laboratory abnormalities or other safety that may affect the subject, or test data and&#xD;
             samples. Factors such as family or society collected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dehua Wu</last_name>
    <phone>020-61642136</phone>
    <email>331576705@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dehua Wu</last_name>
      <phone>020-62787693</phone>
      <email>18602062748@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

